Literature DB >> 9631791

Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function.

J Eller1, A Ede, T Schaberg, M S Niederman, H Mauch, H Lode.   

Abstract

STUDY
OBJECTIVE: In patients with severe COPD, acute infective exacerbations are frequent. Streptococcus pneumoniae and Haemophilus influenzae are the most commonly isolated bacteria in sputum cultures from these patients. We hypothesized that in patients with advanced disease, Gram-negative bacteria other than H influenzae play at least an equally important role.
METHODS: We evaluated clinical data and sputum culture results from 211 unselected COPD patients admitted to our hospital with an acute infective exacerbation of COPD. One hundred twelve patients fulfilled our protocol criteria of reliable microbiologic results and reproducible lung function tests; the patients were categorized according to the recently published three stages of severity.
RESULTS: Lung function tests revealed an FEV1 of > or =50% of the predicted value in 30 patients (stage I), an FEV1 of 35% to <50% of the predicted value in 30 patients (stage II), and an FEV1 of < or =35% of the predicted value in 34 patients (stage III). Bacteria were classified into three groups: group 1 contained S pneumoniae and other Gram-positive cocci; group 2, H influenzae and Moraxella catarrhalis; and group 3, Enterobacteriaceae and Pseudomonas spp. For all patients together, the most frequently isolated bacteria were group 3 organisms (Enterobacteriaceae and Pseudomonas spp, 48.2%), followed by group 1 organisms (S pneumoniae and other Gram-positive cocci, 30.4%), and group 2 organisms (H influenzae and M catarrhalis, 21.4%). In stage I patients, 14 of 30 had bacteria from group 1, seven of 30 had group 2, and nine of 30 had group 3. In stage II patients, eight of 30 had group 1 bacteria, 10 of 30 had group 2, and 12 of 30 had group 3. In stage III patients, 12 of 52 had group 1 bacteria, seven of 52 had group 2, and 22 of 52 had group 3. The three groups of bacteria causing infective exacerbations were unevenly distributed among the three severity stages of lung function (p=0.016).
CONCLUSION: There is a correlation between deterioration of lung function and the bacteria isolated from patients with infective exacerbations of COPD. In acute infective exacerbations, Enterobacteriaceae and Pseudomonas spp are the predominant bacteria in patients with an FEV1 < or =35% of the predicted value.

Entities:  

Mesh:

Year:  1998        PMID: 9631791     DOI: 10.1378/chest.113.6.1542

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  63 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

2.  Prevention of lung injury by Muc1 mucin in a mouse model of repetitive Pseudomonas aeruginosa infection.

Authors:  Tsuyoshi Umehara; Kosuke Kato; Yong Sung Park; Erik P Lillehoj; Hideyuki Kawauchi; Kwang Chul Kim
Journal:  Inflamm Res       Date:  2012-05-29       Impact factor: 4.575

3.  Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: Report of the Committee for the Respiratory System, Japan Society of Chemotherapy.

Authors:  A. Saito; Fumio Miki; Kotaro Oizumi; Naoto Rikitomi; Akira Watanabe; Hironobu Koga; Yoshito Niki; Nobuchika Kusano
Journal:  J Infect Chemother       Date:  1999-06       Impact factor: 2.211

4.  Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.

Authors:  T Schaberg; M Möller; T File; K Stauch; H Landen
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

5.  A Prospective Study of Bacteriological Etiology in Hospitalized Acute Exacerbation of COPD Patients: Relationship with Lung Function and Respiratory Failure.

Authors:  Ashok Kuwal; Vinod Joshi; Naveen Dutt; Surjit Singh; Kailash Chand Agarwal; Gopal Purohit
Journal:  Turk Thorac J       Date:  2017-11-29

6.  Identification of outer membrane Porin D as a vitronectin-binding factor in cystic fibrosis clinical isolates of Pseudomonas aeruginosa.

Authors:  Magnus Paulsson; Birendra Singh; Tamim Al-Jubair; Yu-Ching Su; Niels Høiby; Kristian Riesbeck
Journal:  J Cyst Fibros       Date:  2015-06-03       Impact factor: 5.482

7.  Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease.

Authors:  Paschalina Kontou; Kalliopi Chatzika; Georgia Pitsiou; Ioannis Stanopoulos; Paraskevi Argyropoulou-Pataka; Ioannis Kioumis
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

8.  [Community-acquired and nosocomial pneumonia].

Authors:  T Welte
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

Review 9.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

10.  Efficacy of amoxycillin versus amoxycillin/clavulanate in acute exacerbations of chronic pulmonary obstructive disease in primary care.

Authors:  Carl Llor; Silvia Hernández; Anna Ribas; Carmen Alvarez; Josep Maria Cots; Carolina Bayona; Isabel González; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.